套细胞淋巴瘤研究进展：第55届美国血液学会年会报道  

Reports on research progress of mantle cell lymphoma in the 55th ASH annual meeting

作　　者：曹蕾[1] 范磊[1] 徐卫[1] 李建勇[1] 

机构地区：[1]南京医科大学第一附属医院江苏省人民医院血液科,210029

出　　处：《白血病．淋巴瘤》2014年第2期70-72,共3页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81200360、81170488、30971296、81170485）;江苏省自然科学基金（BK2012484、BK2010584）

摘　　要：套细胞淋巴瘤（MCL）是一种高度侵袭性的非霍奇金淋巴瘤,常可累及淋巴结、胃肠道、骨髓等,易出现治疗耐药和疾病进展.第55届美国血液学会年会关于MCL的研究报告涵盖了多个方面：基础研究方面,ATM、POT1等新型突变的发现以及肿瘤微环境机制的提出进一步完善了MCL发病机制；预后指标方面,基于分子技术的微小残留病灶检测及全基因组甲基化分析等手段为MCL预后和疗效监测提供了新的工具,实现分层治疗；来那度胺、苯达莫司汀、利妥昔单抗及自体造血干细胞移植等的合理使用为MCL老年患者的治疗提供了新方向,ibrutinib、ABT-199及MLN8237等新型药物在初期临床试验显示出令人鼓舞的结果,为MCL治疗提供了新的希望.Mantle cell lymphoma （MCL） , as a kind of highly aggressive non-Hodgkin＇s lymphoma, is characterized by malignant B cell infiltration of lymph node, gastrointestinal tract and bone marrow. Patients suffering from MCL are prone to drug resistance or progression of disease. The 55th ASH annual meeting about MCL explored all aspects. In preclinical research aspects： new mutations including ATM, POT1 and tumor microenvironment further improved the pathogenesis mechanism of MCL. In prognostic indicators, minimal residual disease detected by molecular techniques and whole genome methylation analysis provided new tools for monitoring MCL prognosis and curative effect to guide further risk stratification and individual treatment. Exploration of high effective and low toxic side effective treatment strategies for elderly MCL patients has become a major focus of the meeting. Chemoimmunotherapy including Lenalidomide, bendamustine, rituximab and autologous stem cell transplantation provide more options for the treatment of elderly MCL patients. Novel drugs such as ibrutinib, ABT-199 and MLN8237 have shown encouraging results in preelinieal trials which provide new hope for MCL patients.

关 键 词：套细胞淋巴瘤 美国血液学会年会 

分 类 号：R733.1[医药卫生—肿瘤]